TikTok tic; COVID vaccine and CVST; predict brain injury outcome – mahrgan

Tic-like behaviors after watching certain TikTok, YouTube, and other social media videos are different from the tics in Tourette’s syndrome and may represent a socially-driven functional movement disorder. (Dyskinesia)

Compared with people with normal blood pressure, people diagnosed with high blood pressure between the ages of 35-44 have a smaller total brain volume and are more likely to develop dementia. (hypertension)

5-HT treatment4 The receptor agonist Prudac (Prudac), a drug used to treat chronic idiopathic constipation, can enhance the memory and cognitive abilities of young people. (Translation Psychiatry)

International registration data confirm that patients with cerebral venous sinus thrombosis (CVST) have a very high mortality rate for thrombosis and thrombocytopenia syndrome after vaccination with the adenovirus vector COVID-19. (American Medical Association Neurology)

Dr. David Julius of the University of California, San Francisco and Dr. Ardem Patapoutian of the La Jolla Scripps Research Institute independently discovered information about nervous system signals related to pain or tactile perception, and won the 2021 Nobel Prize in Physiology or Medicine. (New York Times)

In Biogen’s aducanumab (Aduhelm) clinical trial, only six blacks were randomly assigned to the FDA-approved therapeutic dose, although the incidence of Alzheimer’s disease in black elderly is higher than that in whites. (American Medical Association Neurology)

Neurofilament is a marker of axonal injury, which can predict the long-term outcome and progressive neurodegeneration after traumatic brain injury. (Science Translational Medicine)

The prescription information for the migraine prevention drug erenumab (Aimovig) was updated last year, including increased blood pressure, but the researchers pointed out that in clinical trials, erenumab did not show a higher risk of hypertension than placebo. (Headache)

A pilot trial showed that physical and mental intervention is better than standard care for chronic back pain. (Pain report)

Catalyst Pharmaceuticals received a positive decision from the Court of Appeal and overturned the District Court’s decision, which upheld the FDA’s approval of an amifampridine product (Ruzurgi) for use in children with Lambert-Eton myasthenia syndrome (Ruzurgi), despite Catalyst’s treatment of amifampridine (Firdapse). ) Orphan drug franchise for tablets.

  • Judy George reports on neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, multiple sclerosis, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s disease , Amyotrophic lateral sclerosis, concussion, CTE, sleep, pain, etc. follow

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *